AMAnne-Geneviève MarcelinMDVideoHIVEuropean HIV Clinical Forum 2017What is the virological support for reduced drug regimens? | Anne-Geneviève Marcelin, MDView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017Roundtable discussion: Trial design, treatment endpoints and regulatory approachView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017Innovative trial design | Henry Lik Yuen ChanView Video
JFJordan FeldMD, MPHVideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017Combination therapy how to navigate in a minefield of efficacy and toxicity? | Jordan Feld, MD, MPHView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017Other virological mechanisms | Stephen Locarnini, BSc, PhD, MBBS, FRCPView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017HBV Ribonuclease H | John Tavis, PhDView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017RNA interference | Bill Symonds, PharmDView Video
VideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017CCC – DNA inhibition | Anuj Gaggar, MD, PhDView Video
AGAdam GehringPhDVideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017Innate Immunity : TLR, RIG-I, STING and potential others | Adam Gehring, PhDView Video
MMMala MainiMD, PhDVideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017How does HBV interact with the immune system | Mala Maini, MD, PhDView Video
HJHarry JanssenMD, PhDVideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017Is immunomodulation really needed to cure HBV? | Harry Janssen, MD, PhDView Video
FZFabien ZoulimMD, PhDVideoViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2017Hepatitis B Cure: From Discovery to Regulatory Endpoints in HBV clinical research: A summary of the AASLD/EASL statement | Fabien Zoulim, MD, PhDView Video
